- Home
- HTBI vs CRMD Comparison
HTBI vs CRMD Comparison
Compare HTBI & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- CRMD
- Stock Information
- Founded
- HTBI 1926
- CRMD 2006
- Country
- HTBI United States
- CRMD United States
- Employees
- HTBI N/A
- CRMD N/A
- Industry
- HTBI Savings Institutions
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- HTBI Finance
- CRMD Health Care
- Exchange
- HTBI Nasdaq
- CRMD Nasdaq
- Market Cap
- HTBI 641.9M
- CRMD 753.6M
- IPO Year
- HTBI 2012
- CRMD 2010
- Fundamental
- Price
- HTBI $36.94
- CRMD $10.57
- Analyst Decision
- HTBI Buy
- CRMD Strong Buy
- Analyst Count
- HTBI 4
- CRMD 6
- Target Price
- HTBI $39.00
- CRMD $15.67
- AVG Volume (30 Days)
- HTBI 42.1K
- CRMD 1.5M
- Earning Date
- HTBI 01-23-2025
- CRMD 03-11-2025
- Dividend Yield
- HTBI 1.30%
- CRMD N/A
- EPS Growth
- HTBI N/A
- CRMD N/A
- EPS
- HTBI 3.20
- CRMD N/A
- Revenue
- HTBI $193,436,000.00
- CRMD $12,262,234.00
- Revenue This Year
- HTBI N/A
- CRMD N/A
- Revenue Next Year
- HTBI $3.67
- CRMD $246.41
- P/E Ratio
- HTBI $11.33
- CRMD N/A
- Revenue Growth
- HTBI 4.69
- CRMD 41184.20
- 52 Week Low
- HTBI $23.55
- CRMD $2.89
- 52 Week High
- HTBI $38.99
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- HTBI 61.69
- CRMD 40.80
- Support Level
- HTBI $35.68
- CRMD $11.90
- Resistance Level
- HTBI $38.22
- CRMD $12.67
- Average True Range (ATR)
- HTBI 1.07
- CRMD 0.73
- MACD
- HTBI 0.30
- CRMD -0.27
- Stochastic Oscillator
- HTBI 81.24
- CRMD 2.12
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.